振东制药(300158) - 2016年1月5日投资者关系活动记录表

Group 1: Company Strategy and Development - The company is not undergoing a transformation but rather a significant change since its strategic direction has been clear since 2003, focusing on traditional Chinese medicine, oncology drugs, and the major product series of Sophora flavescens [2][3] - The company has acquired several firms, including Tai Sheng Pharmaceutical, Kai Yuan Pharmaceutical, and An Te Biological Pharmaceutical, leading to a diversified development strategy [3] - The company aims to enhance brand awareness and sales through mergers and acquisitions, particularly in the OTC drug market, leveraging the brand of Kangyuan Pharmaceutical's calcium D3 preparation, which is a leading brand in the calcium supplement market [3][4] Group 2: Market Challenges and Responses - Current medical insurance policies significantly impact high-priced major products, but low-priced minor products remain less affected; the company's flagship product, Yan Shu, still has considerable potential for development [3][4] - The company will not diversify further despite changes in national medical policies; it will focus on existing products and enhance the quality of its offerings [4][5] Group 3: Research and Development Focus - The company is concentrating on oncology drugs, which are a global challenge, while also addressing major diseases in China, such as hepatitis B and diabetes [5][6] - Recent developments include obtaining clinical approval for a new drug, Laloheza lipid microsphere injection, which has stronger anti-tumor activity than existing treatments [5][6] Group 4: Sales and Market Positioning - The company does not plan to significantly expand its sales team but will enhance the academic capabilities and overall quality of its personnel; in 2016, the focus will be on structural adjustments and reducing sales expenses [5][6] - The acquisition of Kangyuan Pharmaceutical was aimed at improving the company's market value management and leveraging its sales advantages to boost the sales and profits of calcium preparations [5][6]